19.07.2018 • NewsElaine BurridgeSynthos

Synthos to Build XPS Plant in Poland

Synthos to Build XPS Plant in Poland (c) kodda/Getty Images
Synthos to Build XPS Plant in Poland (c) kodda/Getty Images

Synthos is planning to build a new plant for the production of extruded polystyrene (XPS) at its site in Oswiecim, Poland.

Preparations are already underway to start work and obtain the necessary building permit for the facility, which will have an annual capacity of 220,000 m3. A start-up date was not given.

In addition to traditional PS feedstock, the plant’s process will also use recycled material from styrene packaging waste.

The company said the expansion is in response to rising demand in central Europe, noting that consumption of XPS boards is growing faster than that for traditional foamed PS, both of which are used for insulation. The additional output, Synthos said, will help to boost its sales efforts and increase market share, particularly in Poland, Czech Republic, Slovakia and Germany.

The Polish group also disclosed that, in addition to the Oswiecim project, it is planning another XPS expansion to reach a total capacity of 800,000 m3. Synthos said it is considering a location in the Czech Republic for this expansion. Currently, total combined production at its plants in Oswiecim (before the aforementioned project) and Kralupy in the Czech Republic is 400,000 m3.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.